search
Back to results

Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD (DRNERD)

Primary Purpose

Gastroesophageal Reflux Disease

Status
Withdrawn
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
rabeprazole
standard dose rabeprazole
Sponsored by
Inje University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastroesophageal Reflux Disease focused on measuring Gastroesophageal reflux disease, Proton pump inhibitor, standard dose, Double dose

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • heartburn and/or reflux at least twice weekly in the absence of visible esophageal mucosal breaks at endoscopy

Exclusion Criteria:

  • pregnancy
  • lactation
  • Hx of gastric surgery
  • Hx of gastric cancer or peptic ulcer
  • major medical problems (including CHF, renal failure, COPD, asthma, liver cirrhosis)
  • severe systemic illness
  • Hx of malignancy, allergy Hx to rabeprazole
  • patients who had taken antibiotics
  • antisecretory agents including H2-blocker
  • PPI within 4 weeks before endoscopy
  • current usage of steroids, NSAIDs, aspirin, anticoagulant medication

Sites / Locations

  • Haeundae Paik Hospital, Inje University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Double dose rabeprazole

standard dose rabeprazole

Arm Description

Rabeprazole 20m bid per day will be given for 2 weeks

rabeprazole 20mg per day will bi given for 2 weeks

Outcomes

Primary Outcome Measures

symptom improvement at 2 week after double dose rabeprazole treatment
symptom improvement according to FSSG(the frequency scale for the symptoms of GERD) at 2 week after double dose rabeprazole treatment

Secondary Outcome Measures

sustained symptom improvement at 6 week after treatment
sustained symptom improvement assessed by FSSG(the frequency scale for the symptoms of GERD)score at 6 week after treatment

Full Information

First Posted
July 11, 2011
Last Updated
January 16, 2012
Sponsor
Inje University
search

1. Study Identification

Unique Protocol Identification Number
NCT01391715
Brief Title
Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD
Acronym
DRNERD
Official Title
Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2012
Overall Recruitment Status
Withdrawn
Why Stopped
patients could not be recuited within study duration
Study Start Date
August 2011 (undefined)
Primary Completion Date
October 2012 (Anticipated)
Study Completion Date
December 2012 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Inje University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To the best of our knowledge, there has been no randomized controlled trial to compare double dose PPI therapy with standard one dose PPI therapy for NERD patients. Thus, we hypothesize that a double dose PPI would accelerate and sustain the control of symptom in NERD patients.
Detailed Description
In Asian, the majority of GERD cases are cases of nonerosive reflux esophagitis(NERD). NERD is a difficult -to-treat acid reflux condition even with PPI compared to reflux esophagitis(RE). In addition, the quality of life of NERD patients is quite low, NERD patients need quicker and more effective treatment options. At present, PPI-based step-down treatment is recommended for GERD patients. Doubling th PPI dose has become a commonly practiced therapeutic strategy in patients with GERD who failed PPI once daily. In patients with symptomatic GERD who failed the one dose PPI can increase the rate of overall symptom improvement by 22-26%. There are various mechanisms for standard dose PPI failure in GERD patients. Esophageal hypersensitivity is likely the underlying mechanism in a significant number of patients. Patients with the sensitive esophagus (normal endoscopy and pH test but positive symptom index) were more likely to respond to PPI twice a day. It is thus of clinical interest to determine whether an increased dosage of PPI can achieve rapidly the control of symptoms for patient with NERD patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux Disease
Keywords
Gastroesophageal reflux disease, Proton pump inhibitor, standard dose, Double dose

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Double dose rabeprazole
Arm Type
Active Comparator
Arm Description
Rabeprazole 20m bid per day will be given for 2 weeks
Arm Title
standard dose rabeprazole
Arm Type
Placebo Comparator
Arm Description
rabeprazole 20mg per day will bi given for 2 weeks
Intervention Type
Drug
Intervention Name(s)
rabeprazole
Intervention Description
rabeprazole 20mg bid per day for 2 weeks
Intervention Type
Drug
Intervention Name(s)
standard dose rabeprazole
Intervention Description
rabeprazole 20mg qd per day for 2 weeks
Primary Outcome Measure Information:
Title
symptom improvement at 2 week after double dose rabeprazole treatment
Description
symptom improvement according to FSSG(the frequency scale for the symptoms of GERD) at 2 week after double dose rabeprazole treatment
Time Frame
Two weeks
Secondary Outcome Measure Information:
Title
sustained symptom improvement at 6 week after treatment
Description
sustained symptom improvement assessed by FSSG(the frequency scale for the symptoms of GERD)score at 6 week after treatment
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: heartburn and/or reflux at least twice weekly in the absence of visible esophageal mucosal breaks at endoscopy Exclusion Criteria: pregnancy lactation Hx of gastric surgery Hx of gastric cancer or peptic ulcer major medical problems (including CHF, renal failure, COPD, asthma, liver cirrhosis) severe systemic illness Hx of malignancy, allergy Hx to rabeprazole patients who had taken antibiotics antisecretory agents including H2-blocker PPI within 4 weeks before endoscopy current usage of steroids, NSAIDs, aspirin, anticoagulant medication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tae Oh Kim, M.D. PhD.
Organizational Affiliation
Internal Medicine, Haeundae Paik Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Eun Hee Seo, M.D
Organizational Affiliation
Internal Medicine, Haeundae Paik Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Haeundae Paik Hospital, Inje University School of Medicine
City
Busan
ZIP/Postal Code
612-030
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD

We'll reach out to this number within 24 hrs